Welcome to Medpharm Publications

Medpharm Publications was founded in 1988 and has established itself as the largest medical and pharmaceutical journal publisher in South Africa.

With a publications list of more than ten titles comprising of over fifty journal editions, Medpharm Publications reach more than 40 000 healthcare workers countrywide with printed editions, and has established a global audience with the online editions.

The majority of Medpharm Publications’ journals are associated with professional or scholarly societies and acts as the official South African mouthpiece in the associated discipline. All journals are web-based, most of which are fully peer-reviewed, with five titles accredited by the South African Department of Higher Education and Training (DHET) to earn research subsidies for academic departments.

As a publisher, passionate about journal publishing, we believe that South African researchers and clinicians can and will make a significant contribution to world medical literature.

One Africa, one cure: Making CAR-T Cell therapy accessible across Africa

CAR-T cell therapy is a form of personalised medicine in which a person’s own immune cells are collected and modified in a specialised laboratory so they can better recognise and attack certain blood cancers. It is used in some countries for patients with specific types of lymphoma and leukaemia when other treatments have not worked. It is only available in a few highly specialised hospitals around the world.

Rare Disease Day 2026 puts equity for patients in the spotlight

Rare diseases each affect relatively small numbers of people, but collectively they impact more than 300 million individuals worldwide across over 7,000 known conditions, with 70% of these starting in childhood.1 For many patients and families, the reality is often long diagnostic journeys, uncertainty and ongoing challenges in accessing treatment and support.

Sanofi receives registration for Beyfortus® in South Africa to protect infants against RSV

Sanofi is pleased to share that the South African Health Products Regulatory Authority (SAHPRA) has granted registration for Beyfortus® (nirsevimab), a long-acting monoclonal antibody designed to protect infants against Respiratory Syncytial Virus (RSV).

Cipla partners with ImmunoACT to launch talicabtagene autoleucel, an anti-CD19 CAR-T cell therapy for blood cancers in Africa

Cipla Limited (BSE: 500087; NSE: CIPLA; and hereafter referred to as “Cipla”), through its subsidiary Medpro Pharmaceutica, has entered into an exclusive license and supply agreement with Immunoadoptive Cell Therapy Private Limited (ImmunoACT). Under this partnership, Cipla will commercialize talicabtagene autoleucel, India’s first indigenously developed CAR-T cell therapy, in the Republic of South Africa, Algeria, and Morocco.

The mouth–body connection: Why diabetes and oral health go hand in hand

Every November, National Diabetes Month invites South Africans to take a closer look at one of the country’s most urgent health concerns, and one that’s still growing rapidly. But beyond blood sugar and diet, there’s another piece of the puzzle that often goes unnoticed: the link between oral health and diabetes